TY - JOUR
T1 - Fibromodulin promoted in vitro and in vivo angiogenesis
AU - Jian, Jia
AU - Zheng, Zhong
AU - Zhang, Kermit
AU - Rackohn, Todd Matthew
AU - Hsu, Chingyun
AU - Levin, Andrew
AU - Enjamuri, Dwarak Reddy
AU - Zhang, Xinli
AU - Ting, Kang
AU - Soo, Chia
N1 - Funding Information:
We apologize to all colleagues whose important work we could not cite due to space restrictions. This study was supported by the, Plastic Surgery Research Foundation (2013 National Endowment for Plastic Surgery), and NIH-NIAMS (R43 AR064126). CLSM was performed at the Center for NanoScience Institute Advanced Light Microscopy/Spectroscopy Shared Resource Facility at UCLA, which was supported by funding from NIH-NCRR shared resources grant (CJX1-443835-WS-29646) and NSF Major Research Instrumentation grant (CHE-0722519).
PY - 2013/7/5
Y1 - 2013/7/5
N2 - Fibromodulin (FMOD) is an extracellular matrix (ECM) small leucine-rich proteoglycan (SLRP) that plays an important role in cell fate determination. Previous studies revealed that not only is FMOD critical in fetal-type scarless wound healing, but it also promotes adult wound closure and reduces scar formation. In addition, FMOD-deficient mice exhibit significantly reduced blood vessel regeneration in granulation tissues during wound healing. In this study, we investigated the effects of FMOD on angiogenesis, which is an important event in wound healing as well as embryonic development and tumorigenesis. We found that FMOD accelerated human umbilical vein endothelial HUVEC-CS cell adhesion, spreading, actin stress fiber formation, and eventually tube-like structure (TLS) network establishment in vitro. On a molecular level, by increasing expression of collagen I and III, angiopoietin (Ang)-2, and vascular endothelial growth factor (VEGF), as well as reducing the ratio of Ang-1/Ang-2, FMOD provided a favorable network to mobilize quiescent endothelial cells to an angiogenic phenotype. Moreover, we also confirmed that FMOD enhanced angiogenesis in vivo by using an in ovo chick embryo chorioallantoic membrane (CAM) assay. Therefore, our data demonstrate that FMOD is a pro-angiogenic and suggest a potential therapeutic role of FMOD in the treatment of conditions related to impaired angiogenesis.
AB - Fibromodulin (FMOD) is an extracellular matrix (ECM) small leucine-rich proteoglycan (SLRP) that plays an important role in cell fate determination. Previous studies revealed that not only is FMOD critical in fetal-type scarless wound healing, but it also promotes adult wound closure and reduces scar formation. In addition, FMOD-deficient mice exhibit significantly reduced blood vessel regeneration in granulation tissues during wound healing. In this study, we investigated the effects of FMOD on angiogenesis, which is an important event in wound healing as well as embryonic development and tumorigenesis. We found that FMOD accelerated human umbilical vein endothelial HUVEC-CS cell adhesion, spreading, actin stress fiber formation, and eventually tube-like structure (TLS) network establishment in vitro. On a molecular level, by increasing expression of collagen I and III, angiopoietin (Ang)-2, and vascular endothelial growth factor (VEGF), as well as reducing the ratio of Ang-1/Ang-2, FMOD provided a favorable network to mobilize quiescent endothelial cells to an angiogenic phenotype. Moreover, we also confirmed that FMOD enhanced angiogenesis in vivo by using an in ovo chick embryo chorioallantoic membrane (CAM) assay. Therefore, our data demonstrate that FMOD is a pro-angiogenic and suggest a potential therapeutic role of FMOD in the treatment of conditions related to impaired angiogenesis.
KW - Angiogenesis
KW - Fibromodulin
KW - Human endothelial HUVEC-CS cell
KW - In ovo chick embryo chorioallantoic membrane (CAM) assay
KW - Tube-like structure formation
UR - http://www.scopus.com/inward/record.url?scp=84879883451&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879883451&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2013.06.005
DO - 10.1016/j.bbrc.2013.06.005
M3 - Article
C2 - 23770359
AN - SCOPUS:84879883451
SN - 0006-291X
VL - 436
SP - 530
EP - 535
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 3
ER -